ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Saved in:
| Title: | ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Bandi, Dhana Sekhar Reddy1 (AUTHOR), Nagaraju, Ganji Purnachandra1 (AUTHOR), Sarvesh, Sujith1 (AUTHOR), Carstens, Julienne L.1 (AUTHOR), Foote, Jeremy B.2 (AUTHOR), Graff, Emily C.3 (AUTHOR), Fang, Yu-Hua D4 (AUTHOR), Keeton, Adam B.5,6 (AUTHOR), Chen, Xi5,6 (AUTHOR), Valiyaveettil, Jacob5,6 (AUTHOR), Berry, Kristy L.5 (AUTHOR), Bae, Sejong7 (AUTHOR), Akce, Mehmet1 (AUTHOR), Gorman, Greg8 (AUTHOR), Yoon, Karina J.9,10 (AUTHOR), Manne, Upender11 (AUTHOR), Boyd, Michael R.6 (AUTHOR), Buchsbaum, Donald J.12 (AUTHOR), Azmi, Asfar S.13 (AUTHOR), Maxuitenko, Yulia Y.5 (AUTHOR) |
| Source: | Molecular Cancer. 3/13/2025, Vol. 24 Issue 1, p1-17. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
